{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:09:43Z","timestamp":1785758983477,"version":"3.56.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>For mycophenolic acid (MPA), therapeutic drug monitoring is an essential tool for dosage optimization in transplant recipients and autoimmune diseases. In China, a new commercial kit using an immunochromatographic assay (FICA) with a point-of-care testing system was approved for therapeutic drug monitoring of MPA. However, corroboration between FICA and clinically used assays remains unknown. The authors evaluated MPA concentrations in heart transplant recipients obtained by FICA, high-performance liquid chromatography combined with tandem mass spectrometry (LC-MS\/MS), and enzyme-multiplied immunoassay technique (EMIT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Nine heart transplant recipients administered a single mycophenolate mofetil (MMF) dose, and 4 administered multiple MMF doses were enrolled. MPA samples were collected before administration, and after 0.5, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours, and assessed by 2 immunoassays (EMIT and FICA) and LC-MS\/MS. Consistency between methods was evaluated using Passing\u2013Bablok regression and Bland\u2013Altman analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>For Passing\u2013Bablok regression between FICA and LC-MS\/MS, FICA = 0.784 LC-MS\/MS + 0.360 (95% CI slope: 0.739 to 0.829, 95% CI intercept: 0.174\u20130.545). Regardless of a significant observed correlation coefficient (R<jats:sup>2<\/jats:sup> = 0.9126), statistical analyses revealed a significant difference between FICA and the reference LC-MS\/MS method. The mean absolute bias was 0.69 mcg\/mL between FICA and LC-MS\/MS. Bland\u2013Altman plots showed a mean bias of \u22120.23 mcg\/mL (\u00b11.96 SD, \u22122.19 to 1.72 mcg\/mL) and average relative bias of 14.73% (\u00b11.96 SD, \u221267.91% to 97.37%) between FICA and LC-MS\/MS. Unsatisfactory consistency was observed between EMIT and LC-MS\/MS, and FICA and EMIT. Differences between pharmacokinetic parameters after a single or 7 days of MMF administration, by LC-MS\/MS and FICA, were not statistically significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The consistency of the new FICA using a point-of-care testing device with LC-MS\/MS and EMIT was inadequate, and the accuracy of EMIT and LC-MS\/MS was inappropriate. Clinicians should be informed when switching MPA detection methods to avoid misleading results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000861","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T11:03:11Z","timestamp":1609153391000},"page":"630-636","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of a Point-of-Care Testing with Enzyme-Multiplied Immunoassay Technique and Liquid Chromatography Combined With Tandem Mass Spectrometry Methods for Therapeutic Drug Monitoring of Mycophenolic Acid: A Preliminary Study"],"prefix":"10.1097","volume":"43","author":[{"given":"Hong","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan;"},{"name":"Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan;"},{"name":"Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan;"},{"name":"Department of Pharmacy, the Third People's Hospital of Chengdu, Chengdu; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan;"},{"name":"Department of Pharmacy, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital and Chongqing Cancer Institute, Chongqing Cancer Hospital, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan;"},{"name":"Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan;"},{"name":"Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/FTD.0b013e3181aa36cd","article-title":"New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation","volume":"31","author":"de Jonge","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000351180","article-title":"Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients","volume":"37","author":"Li","year":"2013","journal-title":"Am J Nephrol."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1258\/0004563021902035","article-title":"Monitoring mycophenolic acid","volume":"39","author":"Holt","year":"2002","journal-title":"Ann Clin Biochem."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation","volume":"5","author":"Kuypers","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1097\/01.ASN.0000087540.41388.AD","article-title":"Immunosuppression with mycophenolic acid: one size does not fit all","volume":"14","author":"Bennett","year":"2003","journal-title":"J Am Soc Nephrol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1600-6143.2009.02678.x","article-title":"Mycophenolate blood level monitoring: recent progress","volume":"9","author":"van Gelder","year":"2009","journal-title":"Am J Transpl."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.trac.2016.01.031","article-title":"Liquid chromatography tandem mass spectrometry for therapeutic drug monitoring of immunosuppressive drugs: achievements, lessons and open issues","volume":"84","author":"Shipkova","year":"2016","journal-title":"TrAC Trends in Analytical Chemistry."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00007691-200002000-00030","article-title":"Evaluation of an immunoassay for mycophenolic acid","volume":"22","author":"Sch\u00fctz","year":"2000","journal-title":"Ther Drug Monit."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0041-1345(98)01936-8","article-title":"Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite","volume":"31","author":"Shipkova","year":"1999","journal-title":"Transpl Proc."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1515\/cclm-2018-0891","article-title":"Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab","volume":"57","author":"Van den Bossche","year":"2019","journal-title":"Clin Chem Lab Med."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/apt.13757","article-title":"Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays","volume":"44","author":"Afonso","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000500138","article-title":"Risk factors for new-onset diabetes mellitus after heart transplantation in Chinese patients: a single center experience","volume":"74","author":"Zhang","year":"2019","journal-title":"Ann Nutr Metab."},{"key":"R15-20250603","first-page":"1326","article-title":"Determination of mycophenolic acid in plasma concentration by LC-MS\/MS method and its pharmacokinetic in heart transplant patients","volume":"38","author":"Xiao-ya","year":"2019","journal-title":"Her Med."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2147\/PPA.S119719","article-title":"Utility of the morisky medication adherence scale in gout: a prospective study","volume":"10","author":"Tan","year":"2016","journal-title":"Patient Prefer Adherence."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FTD.0000000000000269","article-title":"Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee","volume":"38","author":"Seger","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-9120(00)00184-3","article-title":"Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients","volume":"34","author":"Shaw","year":"2001","journal-title":"Clin Biochem."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/lt.21895","article-title":"Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients","volume":"15","author":"Shen","year":"2009","journal-title":"Liver Transpl."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/10408363.2017.1399336","article-title":"Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) - does it leverage any advantage in clinical decision making?","volume":"54","author":"Florkowski","year":"2017","journal-title":"Crit Rev Clin Lab Sci."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ajcp\/aqw087","article-title":"Process optimization to improve immunosuppressant drug testing turnaround time","volume":"146","author":"Barakauskas","year":"2016","journal-title":"Am J Clin Pathol."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.acc.2016.04.001","article-title":"Therapeutic drug monitoring of mycophenolic acid","author":"Dasgupta","year":"2016","journal-title":"Adv Clin Chem."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/lt.21607","article-title":"Comparison of a new enzymatic assay with a high-performance liquid chromatography\/ultraviolet detection method for therapeutic drug monitoring of mycophenolic acid in adult liver transplant recipients","volume":"14","author":"Blanchet","year":"2008","journal-title":"Liver Transpl."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/01.ftd.0000197092.84935.ef","article-title":"Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry","volume":"28","author":"Pr\u00e9maud","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/00007691-200412000-00005","article-title":"Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring","volume":"26","author":"Pr\u00e9maud","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/FTD.0000000000000151","article-title":"A Comparison of the immunochemical Methods, PETINIA and EMIT, with that of HPLC-UV for the routine monitoring of mycophenolic acid in heart transplant patients","volume":"37","author":"Kunicki","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0041-1345(98)00201-2","article-title":"Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites","volume":"30","author":"Sch\u00fctz","year":"1998","journal-title":"Transpl Proc."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/clinchem\/44.7.1481","article-title":"Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure","volume":"44","author":"Shipkova","year":"1998","journal-title":"Clin Chem."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:14:40Z","timestamp":1748970880000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000861","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"2020-08-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}